ALK-Abello to acquire Fornix's Dutch allergy division
This article was originally published in Scrip
Executive Summary
ALK-Abello is to acquire Artu Biologicals, the Dutch allergy division of Fornix BioSciences, for €19.6 million in cash. The low sale price "reflects general market conditions in the Netherlands, where the authorities have implemented tightened reimbursement rules for allergy vaccines", said Denmark-based ALK.